Marchione: We are in discussions to fund a clinical trial for BPC-157
Max Marchione · The Great Peptide Debate with Martin Shkreli & Max Marchione · Mar 23, 2026 · at 16:18
Health tech founder Max Marchione outlines his plans to scientifically test BPC-157 during a debate with Martin Shkreli.
0:00 / 0:05exact quote · 6.0s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“We're in the process of chatting with the people required to set up a clinical trial for this, because we will put our money where our mouth is”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Max Marchione
Marchione: Legalizing peptide compounding is the main way to minimize risk
“People are taking these compounds, right? They're already using them at scale, right? And the way to minimize risk, the main way to minimize risk is to move them from category two to category one, right? To legalize them because the risky thing is the dodgy su…”
Marchione: Millions of patients have taken BPC-157 from thousands of doctors
“My statement is thousands do this. My other statement is that millions of patients have taken this. At least hundreds of thousands, I believe millions, have taken this.”
Marchione: Peptides are more viable due to normalization of injections and AI
“I also think as a modality, peptides are one that are more interesting than before, now that injecting is normal. Now the wellness and optimization is normal, not just treating disease, and now that we have AI for things like computational discovery.”
Marchione: Under-researched peptide classes might change the world
“And we've seen one category of peptides GLP-ONE's already changed the world, and my contention is that there are other categories of peptides that are under-researched, but have really interesting kind of clinical vignettes that might change the world going fo…”
Marchione: Majority of gray-market peptide buyers are from middle America
“If you speak, I know dozens of people who own these research use companies, and if you speak to them, the majority of their audience is middle American, not, not, not, not SF tech bros, despite the tech bros being noisy on Twitter.”